JP-1302: a new tool to shed light on the roles of alpha2C-adrenoceptors in brain.
The discovery of JP-1302 as a selective, high affinity antagonist at the alpha2C-adrenoceptor will enable researchers to probe the functional role and address the therapeutic utility of this potentially highly important adrenoceptor subtype.
Tricklebank
M D
MD
Discovery Biology, Eli Lilly and Co. Ltd, Erl Wood Manor, Windlesham, Surrey, UK. TRICKLEBANK_MARK@Lilly.com
D000166:Acridines; D000317:Adrenergic alpha-Antagonists; D000818:Animals; D030801:Animals, Genetically Modified; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology*; D051379:Mice; D010879:Piperazines; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects / Q000502:physiology*
D000166:Acridines; C547775:Adra2c protein, mouse; D000317:Adrenergic alpha-Antagonists; C518829:JP-1302; D010879:Piperazines; D018341:Receptors, Adrenergic, alpha-2